Background:<br> Interferon (IFN) - induced depression represents a major complication in antiviral treatment of chronic hepatitis C virus (HCV) infection.
Aim:<br> To evaluate in a placebo-controlled study the efficacy of a selective serotonin reuptake inhibitor (SSRI) in HCV patients with antiviral therapy and IFN-associated depression.
Methods:<br> In a randomized, double-blind, placebo-controlled study, we included 100 HCV outpatients. During interferon therapy (peginterferon alfa-2b plus ribavirin), depression was monitored using the Hospital Anxiety and Depression Scale (HADS). Patients with clinically relevant IFN-induced depression (HADSâ‰¥9) were randomly assigned to placebo or citalopram (SSRI, 20 mg/day).
Results:<br> In 28 patients (28%), HADS scores increased to â‰¥9 during IFN therapy. They were treated with placebo (n=14) or SSRI (n=14). HADS scores declined significantly in SSRI patients within 4 weeks of therapy (P<0.001) but not in placebo patients. This difference between subgroups was statistically significant (P=0.032). Unblinding became necessary in 5 placebo patients due to intolerable depression. Rescue medication (20 mg citalopram) lead to a significant decrease in HADS scores (P=0.008). All citalopram patients were able to complete IFN therapy as planned. Since an interim analysis showed a significant superiority of SSRI over placebo, the study was terminated prematurely. Three patients, who became depressed afterwards, were treated in an unblinded fashion with citalopram.
Conclusions:<br> Our findings demonstrate clearly that citalopram treatment is highly effective in HCV patients on IFN therapy, when initiated after the onset of clinically relevant depressive symptoms. We suggest that a general SSRI prophylaxis is not necessary in these patients.
- hepatitis C
Statistics from Altmetric.com
competing interests 57/4/531
Competing interests: MRK is a member of the Scientific Advisory Board of Essex Pharma, a subsidiary of Schering-Plough (Kenilworth, New Jersey, USA) and has served on speakers bureaus for Schering-Plough (Kenilworth, New Jersey, USA) and Essex Pharma (Munich, Germany). The other authors have no competing interests.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.